751 related articles for article (PubMed ID: 21663619)
21. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
Kallergi G; Markomanolaki H; Giannoukaraki V; Papadaki MA; Strati A; Lianidou ES; Georgoulias V; Mavroudis D; Agelaki S
Breast Cancer Res; 2009; 11(6):R84. PubMed ID: 19919679
[TBL] [Abstract][Full Text] [Related]
22. Apoptotic circulating tumor cells in early and metastatic breast cancer patients.
Kallergi G; Konstantinidis G; Markomanolaki H; Papadaki MA; Mavroudis D; Stournaras C; Georgoulias V; Agelaki S
Mol Cancer Ther; 2013 Sep; 12(9):1886-95. PubMed ID: 23778153
[TBL] [Abstract][Full Text] [Related]
23. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
[TBL] [Abstract][Full Text] [Related]
24. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Papadaki MA; Nasias D; Matikas A; Mavroudis D; Georgoulias V
Breast Cancer Res; 2015 Aug; 17(1):113. PubMed ID: 26285572
[TBL] [Abstract][Full Text] [Related]
25. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
[TBL] [Abstract][Full Text] [Related]
26. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients.
Bock C; Rack B; Huober J; Andergassen U; Jeschke U; Doisneau-Sixou S
Future Oncol; 2014 Aug; 10(10):1751-65. PubMed ID: 25303055
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
[TBL] [Abstract][Full Text] [Related]
28. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
29. Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system.
Ikeda M; Koh Y; Teraoka S; Sato K; Kanai K; Hayata A; Tokudome N; Akamatsu H; Ozawa Y; Akamatsu K; Endo K; Higuchi M; Nakanishi M; Ueda H; Yamamoto N
Cancer Med; 2020 Mar; 9(6):2122-2133. PubMed ID: 31999390
[TBL] [Abstract][Full Text] [Related]
30. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
[TBL] [Abstract][Full Text] [Related]
31. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
Jiang S; Mao C; Jiang B; Tan Q; Deng B
Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
[TBL] [Abstract][Full Text] [Related]
32. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
Armstrong AJ; Marengo MS; Oltean S; Kemeny G; Bitting RL; Turnbull JD; Herold CI; Marcom PK; George DJ; Garcia-Blanco MA
Mol Cancer Res; 2011 Aug; 9(8):997-1007. PubMed ID: 21665936
[TBL] [Abstract][Full Text] [Related]
33. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
Chebouti I; Kasimir-Bauer S; Buderath P; Wimberger P; Hauch S; Kimmig R; Kuhlmann JD
Oncotarget; 2017 Jul; 8(30):48820-48831. PubMed ID: 28415744
[TBL] [Abstract][Full Text] [Related]
34. Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.
Ito M; Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Saito M
Med Oncol; 2019 Sep; 36(10):89. PubMed ID: 31520329
[TBL] [Abstract][Full Text] [Related]
35. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer.
Lecharpentier A; Vielh P; Perez-Moreno P; Planchard D; Soria JC; Farace F
Br J Cancer; 2011 Oct; 105(9):1338-41. PubMed ID: 21970878
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements.
Kallergi G; Aggouraki D; Zacharopoulou N; Stournaras C; Georgoulias V; Martin SS
Breast Cancer Res; 2018 Jul; 20(1):67. PubMed ID: 29976237
[TBL] [Abstract][Full Text] [Related]
37. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
38. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
39. Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.
Kalykaki A; Agelaki S; Kallergi G; Xyrafas A; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2014 Apr; 73(4):685-93. PubMed ID: 24493157
[TBL] [Abstract][Full Text] [Related]
40. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
